Inventor · disambiguated record
Christian B. Allan
Also filed as: ALLAN CHRISTIAN · ALLAN CHRISTIAN B
19 granted patents·17 pending applications·373 citations·filing 2003–2023
96Inventor score
Top patents by PatentIndex Score
36 records- 0196US7785592B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE LLC·Filed 2007·Granted Aug 31, 2010·33 cites·82 claims
- 0296US7294336B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE INC·Filed 2006·Granted Nov 13, 2007·37 cites·60 claims
- 0395US8309690B2Integrated approach for generating multidomain protein therapeuticsALLAN CHRISTIAN·Filed 2006·Granted Nov 13, 2012·87 cites·25 claims
- 0495US7132100B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE INC·Filed 2003·Granted Nov 7, 2006·49 cites·89 claims
- 0594US8007793B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE LLC·Filed 2010·Granted Aug 30, 2011·21 cites·47 claims
- 0694US7425618B2Stabilized anti-respiratory syncytial virus (RSV) antibody formulationsMEDIMMUNE INC·Filed 2003·Granted Sep 16, 2008·55 cites·55 claims
- 0792US10383948B2Anti-cMet antibody drug conjugates and methods for their useABBVIE INC·Filed 2018·Granted Aug 20, 2019·10 cites·12 claims
- 0892US8206951B2Stabilized liquid anti-RSV antibody formulationsOLIVER CYNTHIA N·Filed 2011·Granted Jun 26, 2012·15 cites·20 claims
- 0992US7691379B2Anti-IL-9 antibody formulationsMEDIMMUNE LLC·Filed 2005·Granted Apr 6, 2010·19 cites·81 claims
- 1092US7585504B2High affinity antibodies against HMGB1 and methods of use thereofMEDIMMUNE LLC·Filed 2005·Granted Sep 8, 2009·21 cites·16 claims
- 1191US10603389B2Anti-cMet antibody drug conjugates and methods for their useABBVIE INC·Filed 2019·Granted Mar 31, 2020·3 cites·4 claims
- 1291US9879067B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE LLC·Filed 2016·Granted Jan 30, 2018·6 cites·32 claims
- 1388US8986686B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE LLC·Filed 2013·Granted Mar 24, 2015·6 cites·17 claims
- 1486US8460663B2Stabilized liquid anti-RSV antibody formulationsOLIVER CYNTHIA N·Filed 2012·Granted Jun 11, 2013·6 cites·15 claims
- 1581US8153131B2High affinity antibodies against HMGB1 and methods of use thereofWU HERREN·Filed 2009·Granted Apr 10, 2012·4 cites·18 claims
- 1681US2023321271A1ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1777US9272032B2Stabilized liquid anti-RSV antibody formulationsMEDIMMUNE LLC·Filed 2014·Granted Mar 1, 2016·1 cites·33 claims
- 1875US11180542B2Stabilized liquid anti-RSV antibody formulationsAREXIS AB·Filed 2020·Granted Nov 23, 2021·0 cites·19 claims
- 1970US10604560B2Stabilized liquid anti-RSV antibody formulationsAREXIS AB·Filed 2017·Granted Mar 31, 2020·0 cites·11 claims
- 2066US2020215200A1ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE INC·Filed 2020·Application pending·0 cites
- 2164US2009053238A1Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody FormulationsMEDIMMUNE INC·Filed 2006·Application pending·0 cites
- 2262US2010303736A1Anti-il-9 antibody formulations and uses thereofMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 2362US2008071063A1Protein FormulationsMEDIMMUNE INC·Filed 2007·Application pending·0 cites
- 2460US2004208870A1Stabilized high concentration anti-integrin alphanubeta3 antibody formulationsMEDIMMUNE INC·Filed 2004·Application pending·0 cites
- 2560US2009175883A1Stabilized anti-respiratory syncytial virus (RSV) antibody formulationsMEDIMMUNE INC·Filed 2008·Application pending·0 cites
- 2658US2017348429A1ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2757US2011172155A1Beta thymosin fragmentsREGENERX BIOPHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 2855US2004208869A1Uses of anti-integrin alphanubeta3 antibody formulationsMEDIMMUNE INC·Filed 2004·Application pending·0 cites
- 2950US2012045456A1Stabilized anti-respiratory syncytial virus (rsv) antibody formulationsOLIVER CYNTHIA N·Filed 2011·Application pending·0 cites
- 3049US2007110757A1Antibody formulations having optimized aggregation and fragmentation profilesWEI ZIPING·Filed 2006·Application pending·0 cites
- 3148US2013196912A1Beta thymosin fragmentsREGENERX BIOPHARMACEUTICALS·Filed 2013·Application pending·0 cites
- 3245US2010129379A1Stabilized antibody formulations and uses thereofCARPENTER JOHN·Filed 2007·Application pending·0 cites
- 3341US2010254985A1Protein FormulationsMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 3441US2010278929A1Antibody formulations having optimized aggregation and fragmentation profilesMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 3540US9504730B2Method of achieving a thymosin beta 4 concentration in a human patientALLAN CHRISTIAN B·Filed 2011·Granted Nov 29, 2016·0 cites·23 claims
- 3640US2015203561A1Beta thymosin fragmentsREGENERX BIOPHARMACEUTICALS·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →